Therapeutic cancer vaccination against telomerase: clinical developments in melanoma.

ABSTRACT:

Purpose of review

Checkpoint inhibitors (CPIs) have revolutionized treatment outcomes for patients with malignant melanoma. Long-term follow-up shows that a substantial subset of patients who exhibit clinical responses achieve extended overall survival. Nevertheless, most patients do not achieve durable benefit from CPIs, and improvements are urgently needed. The clinical efficacy of CPIs depends on highly variable preexisting spontaneous T-cell immune responses. Cancer vaccines represent an independent treatment modality uniquely capable of expanding the repertoire of tumor-specific T cells in cancer patients and thus have the capacity to compensate for the variability in spontaneous T-cell responses. Vaccines are, therefore, considered attractive components in a CPI-combination s

SUBMITTER: Ellingsen EB 

PROVIDER: S-EPMC9894137 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature